A polymeric micelle MRI contrast agent with changeable relaxivity

2006 ◽  
Vol 114 (3) ◽  
pp. 325-333 ◽  
Author(s):  
Emiko Nakamura ◽  
Kimiko Makino ◽  
Teruo Okano ◽  
Tatsuhiro Yamamoto ◽  
Masayuki Yokoyama
Keyword(s):  
Contrast Agent ◽  
Polymeric Micelle ◽  
Mri Contrast Agent ◽  
Mri Contrast

PEG-poly(L-lysine)-based polymeric micelle MRI contrast agent: Feasibility study of a Gd-micelle contrast agent for MR lymphography

2017 ◽  
Vol 47 (1) ◽  
pp. 238-245 ◽  
Author(s):  
Hiroyuki Akai ◽  
Kouichi Shiraishi ◽  
Masayuki Yokoyama ◽  
Koichiro Yasaka ◽  
Masanori Nojima ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Feasibility Study ◽  
Polymeric Micelle ◽  
Mri Contrast Agent ◽  
Mri Contrast ◽  
Mr Lymphography

scholarly journals Evaluation of non-targeting, C- or N-pH (low) insertion peptide modified superparamagnetic iron oxide nanoclusters for selective MRI of liver tumors and their potential toxicity in cirrhosis

RSC Advances ◽  
2019 ◽  
Vol 9 (25) ◽  
pp. 14051-14059
Author(s):  
Abdulrahman Ahmed Mahmood ◽  
Jianqi Zhang ◽  
Rufang Liao ◽  
Xiwei Pan ◽  
Dan Xu ◽  
...  
Keyword(s):  
Iron Oxide ◽  
Liver Cancer ◽  
Contrast Agent ◽  
Cancer Diagnosis ◽  
Liver Tumors ◽  
Superparamagnetic Iron Oxide ◽  
Mri Contrast Agent ◽  
Potential Toxicity ◽  
Mri Contrast ◽  
Specific Enhancement

The acid-responsive pHLIP modified SPION as an MRI contrast agent for liver cancer diagnosis requires the validation of both the tumor-specific enhancement and a safe profile in cirrhosis.

Gd2O3 nanoparticles as a positive MRI contrast agent for cell uptake

2010 ◽  
Author(s):  
N. Riyahi-Alam ◽  
J. Behrouzkia ◽  
S. Haghgoo ◽  
A Seifalian ◽  
R Zohdi Aghdam. ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Mri Contrast Agent ◽  
Cell Uptake ◽  
Mri Contrast ◽  
Gd2o3 Nanoparticles

scholarly journals Biocompatibility of Bacterial Magnetosomes as MRI Contrast Agent: A Long-Term In Vivo Follow-Up Study

Nanomaterials ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 1235
Author(s):  
Xiaohui Nan ◽  
Wenjia Lai ◽  
Dan Li ◽  
Jiesheng Tian ◽  
Zhiyuan Hu ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Magnetic Domain ◽  
Bilayer Membrane ◽  
The Body ◽  
Mri Contrast Agent ◽  
Mri Imaging ◽  
Mri Contrast

Derived from magnetotactic bacteria (MTB), magnetosomes consist of magnetite crystals enclosed within a lipid bilayer membrane and are known to possess advantages over artificially synthesized nanoparticles because of the narrow size distribution, uniform morphology, high purity and crystallinity, single magnetic domain, good biocompatibility, and easy surface modification. These unique properties have increasingly attracted researchers to apply bacterial magnetosomes (BMs) in the fields of biology and medicine as MRI imaging contrast agents. Due to the concern of biosafety, a long-term follow-up of the distribution and clearance of BMs after entering the body is necessary. In this study, we tracked changes of BMs in major organs of mice up to 135 days after intravenous injection using a combination of several techniques. We not only confirmed the liver as the well-known targeted organs of BMs, but also found that BMs accumulated in the spleen. Besides, two major elimination paths, as well as the approximate length of time for BMs to be cleared from the mice, were revealed. Together, the results not only confirm that BMs have high biocompatibility, but also provide a long-term in-vivo assessment which may further help to forward the clinical applications of BMs as an MRI contrast agent.

scholarly journals Fluorescent chitosan-based nanohydrogels and encapsulation of gadolinium MRI contrast agent for magneto-optical imaging

2021 ◽  
pp. 100104
Author(s):  
Juliette Moreau ◽  
Maité Callewaert ◽  
Volodymyr Malytskyi ◽  
Céline Henoumont ◽  
Sorina N. Voicu ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Optical Imaging ◽  
Mri Contrast Agent ◽  
Mri Contrast

scholarly journals Study on Establishing Reference Safe Concentrations of MRI Contrast Agents for Optimized Images: Paramagnetic Gd-DTPA-BMEA and Superparamagnetic Ferucarbotran

2021 ◽  
Vol 11 (3) ◽  
pp. 1165
Author(s):  
Wen-Tien Hsiao ◽  
Yi-Hong Chou ◽  
Jhong-Wei Tu ◽  
Ai-Yih Wang ◽  
Lu-Han Lai
Keyword(s):  
Contrast Agent ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Mri Contrast Agent ◽  
In Vitro Experiments ◽  
Mri Contrast ◽  
In Vivo Experiments ◽  
Contrast Agent Injection

The purpose of this study is to establish the minimal injection doses of magnetic resonance imaging (MRI) contrast agents that can achieve optimized images while improving the safety of injectable MRI drugs. Gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA) and ferucarbotran, commonly used in clinical practice, were selected and evaluated with in vitro and in vivo experiments. MRI was acquired using T1-weighted (T1W) and T2-weighted (T2W) sequences, and the results were quantitatively analyzed. For in vitro experiments, results showed that T1W and T2W images were optimal when Gd-DTPA-bisamide (2-oxoethyl) (Gd-DTPA-BMEA) and ferucarbotran were diluted to a volume percentage of 0.6% and 0.05%; all comparisons were significant differences in grayscale statistics using one-way analysis of variance (ANOVA). For in vivo experiments, the contrast agent with optimal concentration percentages determined from in vitro experiments were injected into mice with an injection volume of 100 μL, and the images of brain, heart, liver, and mesentery before and after injection were compared. The statistical results showed that the p values of both T1W and T2W were less than 0.001, which were statistically significant. Under safety considerations for MRI contrast agent injection, optimized MRI images could still be obtained after reducing the injection concentration, which can provide a reference for the safety concentrations of MRI contrast agent injection in the future.

Sign in / Sign up

Export Citation Format

Share Document